How New US Tariffs on Generic Medicines Could Impact India's Pharma Industry

The recent announcement of steep tariffs by the US on generic medicines poses significant challenges for India's pharmaceutical exports, which heavily rely on the US market. While the tariffs may not uniformly impact all products, they could lead to increased costs for US healthcare providers and patients. The Global Trade Research Initiative suggests that India should diversify its export markets to mitigate risks. With India being a major supplier of affordable generics, the implications of these tariffs could reshape the global pharmaceutical landscape. This article delves into the details of the tariffs, their potential effects on India's pharma industry, and the broader market dynamics.

By Narendra Chaudhary Jul 22, 2026, 16:14 IST

Significant Changes Ahead for India's Pharmaceutical Exports

New Delhi: The recent announcement of steep tariffs by the United States on generic medications is poised to have a considerable impact on India's primary pharmaceutical export market, according to the Global Trade Research Initiative (GTRI).

Nonetheless, the think tank noted that the repercussions may not be uniform across the board.

Many Indian generic drugs are priced significantly lower—by seven to ten times—compared to their branded counterparts. Even with a potential 100% tariff, these generics could still be more affordable than branded options, suggesting that the increased costs may be absorbed by US healthcare providers, insurers, and patients rather than halting Indian exports immediately.

The most significant challenges are anticipated for higher-value generic formulations and branded generics, where domestic manufacturing in the US may become a viable option.

Ajay Srivastava, founder of GTRI, emphasized that the proposed tariffs could greatly influence India's largest pharmaceutical export market. He also urged India to diversify its export destinations, focusing on Europe, Latin America, Africa, and Asia.

Understanding Generic Medicines:

Generic medicines are those that have lost patent protection and contain the same active ingredients, strength, dosage form, and therapeutic effects as their branded versions, but are marketed under their generic names or alternative brand names, typically at lower prices.

Trump's Announcement:

In a statement on Truth Social, US President Donald Trump declared that starting August 1, the US will maintain a zero percent tariff on all generic drugs for two years, after which the tariff will rise to 100% for one year and then to 200%.

"This initiative aims to RESHORE Generic Pharmaceutical Production to America, penalizing companies that fail to establish manufacturing facilities within the specified timeframe," Trump stated.

US Pharma Tariff Strategy:

This latest announcement completes Trump's strategy to impose tariffs on nearly all segments of pharmaceutical imports. On April 2, 2026, the administration had already introduced tariffs of up to 100% on certain branded medicines and essential pharmaceutical ingredients under the Section 232 national security framework, while initially excluding generics.

The July 21 announcement now includes generic drugs in the tariff regime, effectively covering all major pharmaceutical categories under Trump's reshoring plan.

US Generic Market Overview:

In 2025, the US imported pharmaceutical products worth USD 213 billion, which included USD 94.1 billion in finished medicines sold in retail packaging, a category that encompasses generic drugs.

According to GTRI, determining the value of generic medicine imports is complex, as US customs data does not separately identify generics. Instead, they are categorized under HS (Harmonised System) 3004, which also includes patented medicines, branded generics, and over-the-counter drugs.

Consequently, estimates are based on industry data rather than customs statistics.

India's Pharmaceutical Exports:

India stands to be significantly affected as a leading exporter of generic drugs. In 2025, the country exported USD 25.8 billion worth of pharmaceuticals, with USD 9.7 billion, or 37.7%, directed to the US, making it India's largest pharmaceutical export market.

Indian firms account for 47% of all generic prescriptions filled in the US, establishing India as the primary source of affordable generic medications. However, due to the low pricing of generics, India's share of the value of US generic imports is estimated at only 30%, which is considerably lower than its share of prescriptions, according to Srivastava.

Several prominent Indian pharmaceutical companies, including Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla, and Dr. Reddy's Laboratories, already operate FDA-approved manufacturing facilities in the US.

Indian generics are commonly prescribed for conditions such as hypertension, diabetes, cancer, infectious diseases, and mental health issues.

Other Key Export Markets for India:

In 2025, India exported pharmaceuticals worth USD 4.05 billion to the EU, USD 783.6 million to the UK, USD 675.9 million to South Africa, USD 636.6 million to Nigeria, USD 596.7 million to Brazil, USD 544 million to Canada, USD 475.2 million to Australia, USD 467.3 million to Russia, USD 408.5 million to the Philippines, and USD 405.2 million to Kenya.